Antiphospholipid antibodies and renal transplant: A systematic review and meta-analysis

Paul RJ Ames, Mira Merashli, Tommaso Bucci, Fabrizio Gentile, Jose Delgado-Alves

Research output: Contribution to journalArticle

Abstract

Objective: To evaluate the effect of antiphospholipid antibodies (aPL) on renal allograft outcome after kidney transplantation. Methods: A systematic search of EMBASE and PubMed databases from inception to July 2018 was run according to PRISMA guidelines; Peto's odds ratio (OR) for rare events was used for the meta-analysis. Results: Our inclusion/exclusion criteria were met by 22 cohort studies having different outcomes: allograft thrombosis (n = 9) and thromboprophylaxis (n = 3), allograft loss from any cause (n = 9), allograft malfunction (n = 3), duration (n = 2), glomerular filtration rate at 1 year (n = 3) and allograft rejection (n = 5). The pooled prevalence of allograft thrombosis and of thrombotic microangiopathy was greater in aPL+ve than negative recipients (10.4% vs 1.7%, p < 0.0001 and 10.2% vs 0%, p = 0.005, respectively). The pooled prevalence of allograft thrombosis was 75% in patients not taking anticoagulation whereas none of the anticoagulated recipients developed thrombosis (p < 0.0001). The pooled prevalence of allograft loss was greater in aPL+ve recipients (28% vs 18% respectively, p < 0.0001); the pooled prevalence of aPL was greater in allograft loss recipients compared to those who did not lose it (51% vs 33%, p < 0.0001). The pooled prevalence of allograft malfunction and rejection was similar in aPL−ve and aPL+ve recipients (32.2% vs 40.3% and 14.9% vs 14.4%, respectively) but graft duration was shorter in aPL+ve than aPL−ve recipients (p = 0.001) and glomerular filtration rate at 1 year was lower in aPL + ve than aPL−ve recipients (p < 0.0001). Conclusion: APL relate strongly to allograft thrombosis, loss and duration but not to allograft malfunction and rejection. Oral antivitamin K anticoagulants effectively prevent allograft thrombosis in aPL recipients. The debate on the role of aPL in renal transplant is limited by the expression of data as percentage of recipients positive for aPL rather than aPL titres in many studies.

Original languageEnglish
Pages (from-to)1041-1052
JournalSeminars in Arthritis and Rheumatism
Volume48
Issue number6
Early online date19 Oct 2018
DOIs
Publication statusPublished - Jun 2019

Fingerprint

Antiphospholipid Antibodies
Allografts
Meta-Analysis
Transplants
Kidney
Thrombosis
Glomerular Filtration Rate
Thrombotic Microangiopathies
PubMed
Kidney Transplantation
Anticoagulants
Cohort Studies

Keywords

  • Antiphospholipid antibodies
  • Renal transplantation

Cite this

@article{a3584ade115b421e8ae2d3fbed81de47,
title = "Antiphospholipid antibodies and renal transplant: A systematic review and meta-analysis",
abstract = "Objective: To evaluate the effect of antiphospholipid antibodies (aPL) on renal allograft outcome after kidney transplantation. Methods: A systematic search of EMBASE and PubMed databases from inception to July 2018 was run according to PRISMA guidelines; Peto's odds ratio (OR) for rare events was used for the meta-analysis. Results: Our inclusion/exclusion criteria were met by 22 cohort studies having different outcomes: allograft thrombosis (n = 9) and thromboprophylaxis (n = 3), allograft loss from any cause (n = 9), allograft malfunction (n = 3), duration (n = 2), glomerular filtration rate at 1 year (n = 3) and allograft rejection (n = 5). The pooled prevalence of allograft thrombosis and of thrombotic microangiopathy was greater in aPL+ve than negative recipients (10.4{\%} vs 1.7{\%}, p < 0.0001 and 10.2{\%} vs 0{\%}, p = 0.005, respectively). The pooled prevalence of allograft thrombosis was 75{\%} in patients not taking anticoagulation whereas none of the anticoagulated recipients developed thrombosis (p < 0.0001). The pooled prevalence of allograft loss was greater in aPL+ve recipients (28{\%} vs 18{\%} respectively, p < 0.0001); the pooled prevalence of aPL was greater in allograft loss recipients compared to those who did not lose it (51{\%} vs 33{\%}, p < 0.0001). The pooled prevalence of allograft malfunction and rejection was similar in aPL−ve and aPL+ve recipients (32.2{\%} vs 40.3{\%} and 14.9{\%} vs 14.4{\%}, respectively) but graft duration was shorter in aPL+ve than aPL−ve recipients (p = 0.001) and glomerular filtration rate at 1 year was lower in aPL + ve than aPL−ve recipients (p < 0.0001). Conclusion: APL relate strongly to allograft thrombosis, loss and duration but not to allograft malfunction and rejection. Oral antivitamin K anticoagulants effectively prevent allograft thrombosis in aPL recipients. The debate on the role of aPL in renal transplant is limited by the expression of data as percentage of recipients positive for aPL rather than aPL titres in many studies.",
keywords = "Antiphospholipid antibodies, Renal transplantation",
author = "Ames, {Paul RJ} and Mira Merashli and Tommaso Bucci and Fabrizio Gentile and Jose Delgado-Alves",
year = "2019",
month = "6",
doi = "10.1016/j.semarthrit.2018.10.016",
language = "English",
volume = "48",
pages = "1041--1052",
journal = "Seminars in Arthritis and Rheumatism",
issn = "0049-0172",
publisher = "W B SAUNDERS CO-ELSEVIER INC",
number = "6",

}

Antiphospholipid antibodies and renal transplant : A systematic review and meta-analysis. / Ames, Paul RJ; Merashli, Mira; Bucci, Tommaso; Gentile, Fabrizio; Delgado-Alves, Jose.

In: Seminars in Arthritis and Rheumatism, Vol. 48, No. 6, 06.2019, p. 1041-1052.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Antiphospholipid antibodies and renal transplant

T2 - A systematic review and meta-analysis

AU - Ames, Paul RJ

AU - Merashli, Mira

AU - Bucci, Tommaso

AU - Gentile, Fabrizio

AU - Delgado-Alves, Jose

PY - 2019/6

Y1 - 2019/6

N2 - Objective: To evaluate the effect of antiphospholipid antibodies (aPL) on renal allograft outcome after kidney transplantation. Methods: A systematic search of EMBASE and PubMed databases from inception to July 2018 was run according to PRISMA guidelines; Peto's odds ratio (OR) for rare events was used for the meta-analysis. Results: Our inclusion/exclusion criteria were met by 22 cohort studies having different outcomes: allograft thrombosis (n = 9) and thromboprophylaxis (n = 3), allograft loss from any cause (n = 9), allograft malfunction (n = 3), duration (n = 2), glomerular filtration rate at 1 year (n = 3) and allograft rejection (n = 5). The pooled prevalence of allograft thrombosis and of thrombotic microangiopathy was greater in aPL+ve than negative recipients (10.4% vs 1.7%, p < 0.0001 and 10.2% vs 0%, p = 0.005, respectively). The pooled prevalence of allograft thrombosis was 75% in patients not taking anticoagulation whereas none of the anticoagulated recipients developed thrombosis (p < 0.0001). The pooled prevalence of allograft loss was greater in aPL+ve recipients (28% vs 18% respectively, p < 0.0001); the pooled prevalence of aPL was greater in allograft loss recipients compared to those who did not lose it (51% vs 33%, p < 0.0001). The pooled prevalence of allograft malfunction and rejection was similar in aPL−ve and aPL+ve recipients (32.2% vs 40.3% and 14.9% vs 14.4%, respectively) but graft duration was shorter in aPL+ve than aPL−ve recipients (p = 0.001) and glomerular filtration rate at 1 year was lower in aPL + ve than aPL−ve recipients (p < 0.0001). Conclusion: APL relate strongly to allograft thrombosis, loss and duration but not to allograft malfunction and rejection. Oral antivitamin K anticoagulants effectively prevent allograft thrombosis in aPL recipients. The debate on the role of aPL in renal transplant is limited by the expression of data as percentage of recipients positive for aPL rather than aPL titres in many studies.

AB - Objective: To evaluate the effect of antiphospholipid antibodies (aPL) on renal allograft outcome after kidney transplantation. Methods: A systematic search of EMBASE and PubMed databases from inception to July 2018 was run according to PRISMA guidelines; Peto's odds ratio (OR) for rare events was used for the meta-analysis. Results: Our inclusion/exclusion criteria were met by 22 cohort studies having different outcomes: allograft thrombosis (n = 9) and thromboprophylaxis (n = 3), allograft loss from any cause (n = 9), allograft malfunction (n = 3), duration (n = 2), glomerular filtration rate at 1 year (n = 3) and allograft rejection (n = 5). The pooled prevalence of allograft thrombosis and of thrombotic microangiopathy was greater in aPL+ve than negative recipients (10.4% vs 1.7%, p < 0.0001 and 10.2% vs 0%, p = 0.005, respectively). The pooled prevalence of allograft thrombosis was 75% in patients not taking anticoagulation whereas none of the anticoagulated recipients developed thrombosis (p < 0.0001). The pooled prevalence of allograft loss was greater in aPL+ve recipients (28% vs 18% respectively, p < 0.0001); the pooled prevalence of aPL was greater in allograft loss recipients compared to those who did not lose it (51% vs 33%, p < 0.0001). The pooled prevalence of allograft malfunction and rejection was similar in aPL−ve and aPL+ve recipients (32.2% vs 40.3% and 14.9% vs 14.4%, respectively) but graft duration was shorter in aPL+ve than aPL−ve recipients (p = 0.001) and glomerular filtration rate at 1 year was lower in aPL + ve than aPL−ve recipients (p < 0.0001). Conclusion: APL relate strongly to allograft thrombosis, loss and duration but not to allograft malfunction and rejection. Oral antivitamin K anticoagulants effectively prevent allograft thrombosis in aPL recipients. The debate on the role of aPL in renal transplant is limited by the expression of data as percentage of recipients positive for aPL rather than aPL titres in many studies.

KW - Antiphospholipid antibodies

KW - Renal transplantation

UR - http://www.scopus.com/inward/record.url?scp=85056475900&partnerID=8YFLogxK

U2 - 10.1016/j.semarthrit.2018.10.016

DO - 10.1016/j.semarthrit.2018.10.016

M3 - Article

VL - 48

SP - 1041

EP - 1052

JO - Seminars in Arthritis and Rheumatism

JF - Seminars in Arthritis and Rheumatism

SN - 0049-0172

IS - 6

ER -